M Zaudig

Summary

Country: Germany

Publications

  1. ncbi A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia
    M Zaudig
    Windach Institute and Hospital of Neurobehavioural Research and Therapy WINTR, Psychosomatic Hospital, Germany
    Drug Saf 23:183-95. 2000

Detail Information

Publications1

  1. ncbi A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia
    M Zaudig
    Windach Institute and Hospital of Neurobehavioural Research and Therapy WINTR, Psychosomatic Hospital, Germany
    Drug Saf 23:183-95. 2000
    ..By treating the latter, risperidone has the potential to be of substantial benefit to patients with dementia, their carers and the costs of healthcare...